The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeuticsnew drug application (NDA) for roflumilast foam 0.3% to treat patients aged nine years and above with seborrheic dermatitis.

The regulator has set 16 December 2023 as a prescription drug user fee act (PDUFA) target action date for the decision on the application.

Roflumilast foam is an investigational, potent and selective phosphodiesterase type 4 (PDE4) inhibitor. The drug is taken once a day and is currently being developed for the treatment of inflammatory dermatoses, mainly in hair-bearing body areas such as the face, the trunk and the scalp.

Arcutis Biotherapeutics president and CEO Frank Watanabe stated: “The acceptance of the NDA for roflumilast foam marks a major milestone toward our goal of bringing a steroid-free, topical foam treatment option to market, addressing a significant unmet need for individuals living with seborrheic dermatitis.

“If approved, roflumilast foam would be the first topical drug with a new mechanism of action for this condition in over two decades, highlighting the unique formulation and deep dermatological expertise that Arcutis brings to immuno-dermatology.”

The NDA submission to the FDA was based on positive data obtained from the Phase II and pivotal Phase III trials of roflumilast foam.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The vehicle-[an inert medium in which a medicinally active agent is administered]controlled, parallel-group, pivotal double-blind Phase III study of roflumilast foam applied topically for the reduction of seborrheic dermatitis (STRATUM) trial was designed to assess the efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis.

The findings showed that the trial met its primary endpoint, with a 79.5% investigator global assessment (IGA) success rate in patients treated with roflumilast foam compared to 58% in individuals treated with the vehicle at the end of week eight.

Roflumilast foam had a favourable safety profile and was also found to be well-tolerated.